GESTIÓN EN SALUD PÚBLICA: Melanoma/Skin Cancer Detection and Prevention Month® (see related measures) 1 | National Quality Measures Clearinghouse 1/3

aportes a la gestión necesaria para la sustentabilidad de la SALUD PÚBLICA como figura esencial de los servicios sociales básicos para la sociedad humana, para la familia y para la persona como individuo que participa de la vida ciudadana.

GESTIÓN EN SALUD PÚBLICA

martes, 1 de mayo de 2018

Melanoma/Skin Cancer Detection and Prevention Month® (see related measures) 1 | National Quality Measures Clearinghouse 1/3

Health Awareness Topics: May 2018

Cutaneous melanoma: proportion of patients with cutaneous melanoma who undergo diagnostic excision biopsy where the surgical pathology report contains a full set of data items (as defined by the current Royal College of Pathologists dataset).

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing wide local excision within 84 days of their diagnostic excision biopsy.

Melanoma: percentage of patients with a melanoma less than or equal to 1 mm thick (i.e., T1) for whom the surgical excision margins are 1 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

Melanoma: percentage of patients with melanoma who have biopsy-proven, palpable nodal disease who do not undergo sentinel lymph node biopsy (SLNB).

Cutaneous melanoma: proportion of patients with cutaneous melanoma who undergo sentinel node biopsy (SNB) where the SNB report contains a full set of data items (as defined by the current Royal College of Pathologists dataset).

Melanoma: percentage of patients with a melanoma in situ (i.e., Tis) for whom the surgical excision margins are 5 mm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

Melanoma: percentage of patients to undergo a sentinel lymph node biopsy (SLNB) for melanoma for whom lymphoscintigraphy is performed to identify the draining nodal basin(s) when drainage to more than one basin is possible.

Melanoma: percentage of patients who undergo an axillary lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least 10 regional lymph nodes are resected and pathologically examined.

Melanoma: percentage of patients who have a stage Ib or II melanoma with whom sentinel lymph node biopsy (SLNB) is discussed.

Cutaneous melanoma: proportion of patients with stage III and IV cutaneous melanoma who undergo CT or positron emission tomography (PET) CT prior to completion lymphadenectomy.

Melanoma: percentage of patients who have a resected primary melanoma metastatic to regional lymph nodes or distant sites for whom there is a documented discussion regarding adjuvant therapy.

Melanoma: percentage of patients with a melanoma for whom the surgeon documented the measured surgical margin in the operative report.

Melanoma: percentage of patients with melanoma having biopsy-proven or palpable nodal disease and no evidence of distant metastases who undergo a lymph node dissection (LND).

Cutaneous melanoma: proportion of patients with cutaneous melanoma who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.

Melanoma: percentage of patient visits, regardless of age, with a new occurrence of melanoma that have a treatment plan documented in the chart that was communicated to the physician(s) providing continuing care within one month of diagnosis.

Cutaneous melanoma: proportion of patients with cutaneous melanoma undergoing diagnostic excision biopsy who undergo a wide local excision.

Melanoma: percentage of patients who undergo a sentinel lymph node biopsy (SLNB) for melanoma for whom the sentinel lymph nodes (SLNs) are sent for permanent sectioning only (no frozen sections), unless a reason is documented.

Melanoma: percentage of patients with a melanoma 1-2 mm thick (i.e., T2) for whom the surgical excision margins are 1-2 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

Melanoma: percentage of patients treated for melanoma for whom stage-specific follow-up, including future skin exams, is discussed and documented.

No hay comentarios:

Publicar un comentario